In summary, we have shown that (1) CD47 mRNA expression correlates with disease progression, (2) CD47 expression is profoundly higher in myeloma cells compared to other populations in patient PBMCs, (3) this expression was downregulated in 3DTEBM cultures, and (4) blocking CD47 on MM cells with anti-CD47 mAb enhanced MM killing by macrophages especially in 3DTEBM, which was mediated by an enhanced phagocytosis. This evidence concerns the gene CD47 and plasma cell myeloma.